<div id="readability-page-1"><p>Daiwa Securities Group Inc. lifted its position in  IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 11.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor  owned 21,298 shares of the company's stock after buying an additional 2,120 shares during the quarter. Daiwa Securities Group Inc.'s holdings in IDEXX Laboratories were worth $11,423,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>IDEXX Laboratories</strong> alerts:</span></p></div><ul><li>Bullish or Bearish? Vetting Animal Health Care Stocks</li></ul><p>A number of other institutional investors have also added to or reduced their stakes in the company. Gerber Kawasaki Wealth &amp; Investment Management acquired a new stake in  IDEXX Laboratories in the second quarter valued at $253,000.  SVB Wealth LLC raised its holdings in shares of  IDEXX Laboratories by 5.1% in the 2nd quarter. SVB Wealth LLC now owns 4,333 shares of the company's stock valued at $2,324,000 after purchasing an additional 212 shares during the period.  Crestmont Private Wealth LLC lifted its stake in  IDEXX Laboratories by 5.5% in the 2nd quarter. Crestmont Private Wealth LLC now owns 908 shares of the company's stock valued at $487,000 after purchasing an additional 47 shares during the last quarter.  Ossiam grew its holdings in  IDEXX Laboratories by 35.2% during the second quarter. Ossiam now owns 6,644 shares of the company's stock worth $3,563,000 after purchasing an additional 1,731 shares during the period.  Finally, California Public Employees Retirement System grew its holdings in  IDEXX Laboratories by 4.7% during the second quarter. California Public Employees Retirement System now owns 148,408 shares of the company's stock worth $79,597,000 after purchasing an additional 6,706 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Analyst Ratings Changes</h2><p>Several analysts have issued reports on the company. UBS Group upped their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the company a &#34;neutral&#34; rating in a research note on Tuesday, November 4th. Jefferies Financial Group  restated a &#34;buy&#34; rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. BTIG Research raised their price target on IDEXX Laboratories from $785.00 to $830.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, November 4th. Barclays started coverage on shares of IDEXX Laboratories in a report on Monday. They issued an &#34;overweight&#34; rating and a $850.00 price objective on the stock. Finally, Morgan Stanley raised their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, November 4th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $763.50.</p><p><b>Get Our Latest Analysis on IDEXX Laboratories</b></p><h2>Insider Activity at IDEXX Laboratories</h2><p>In other news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at approximately $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Corporate insiders own  0.98% of the company's stock. </p><h2>IDEXX Laboratories Stock Up 0.4%</h2><p>IDXX stock opened at $701.83 on Thursday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. The stock has a market capitalization of $56.04 billion, a price-to-earnings ratio of 55.66, a PEG ratio of 4.17 and a beta of 1.67. The business's fifty day moving average price is $680.30 and its two-hundred day moving average price is $617.20. </p><p>IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the company posted $2.80 earnings per share. IDEXX Laboratories's revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS.  On average, equities analysts anticipate that  IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year. </p><h2>IDEXX Laboratories Company Profile</h2> (Free Report)<p>IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than IDEXX Laboratories</li><li>What Makes a Stock a Good Dividend Stock?</li><li>Market Momentum: 3 Stocks Poised for Major Breakouts</li><li>The Most Important Warren Buffett Stock for Investors: His Own</li><li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li><li>3 Best Fintech Stocks for a Portfolio Boost</li><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p><strong>Want to see what other hedge funds are holding IDXX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in IDEXX Laboratories Right Now?</h2><p>Before you consider IDEXX Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.</p><p>While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IDXX

<p>Daiwa Securities Group Inc. increased its stake in IDEXX Laboratories by 11.1% in Q2, owning 21,298 shares valued at $11.42 million. Analysts have issued various ratings, with UBS, Jefferies, BTIG, Barclays, and Morgan Stanley providing price targets ranging from $750 to $850. IDEXX's stock opened at $701.83, with a market cap of $56.04 billion. The company reported Q3 earnings of $3.22 per share, beating estimates.</p>

Daiwa Securities Group Inc. Buys 2,120 Shares of IDEXX Laboratories, Inc. $IDXX